IMAC Holdings (Nasdaq:BACK) - Hisse Senedi Fiyatı, Haberler ve Analizler

BACK Stoklara Genel Bakış

IMAC Holdings, Inc.'in önemli bir faaliyeti bulunmamaktadır. Daha fazla detay

BACK temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	0/6

Risk Analizi

Anlamlı bir piyasa değeri yok ( $2M )

Geliri 1 milyon ABD dolarından az ( $0 )

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Negatif hissedar öz sermayesi

+ 2 daha fazla risk

IMAC Holdings, Inc. Rakipler

SunLink Health Systems

NYSEAM:SSY

US$5.3m

Oncology Institute

NasdaqCM:TOI

US$13.0m

U.S. NeuroSurgical Holdings

OTCPK:USNU

US$13.6m

Inspire Veterinary Partners

NasdaqCM:IVP

US$5.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti IMAC Holdings
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.04
52 Haftanın En Yüksek Seviyesi	US$7.75
52 Haftanın En Düşük Seviyesi	US$0.98
Beta	0.26
11 Aylık Değişim	-14.75%
3 Aylık Değişim	-38.10%
1 Yıllık Değişim	-36.20%
33 Yıllık Değişim	-97.20%
5 Yıllık Değişim	-98.22%
Halka arzdan bu yana değişim	-99.06%

Son Haberler & Güncellemeler

Recent updates

IMAC Holdings, Inc.'s (NASDAQ:BACK) Business And Shares Still Trailing The Industry

Apr 18

Is IMAC Holdings (NASDAQ:IMAC) Using Debt In A Risky Way?

Oct 12

IMAC expands Florida presence with Fort Pierce Chiropractic acquisition for undisclosed amount

Jun 14

We Think IMAC Holdings (NASDAQ:IMAC) Has A Fair Chunk Of Debt

Mar 06

Hissedar Getirileri

	BACK	US Healthcare	US Pazar
7D	1.0%	2.0%	1.6%
1Y	-36.2%	7.5%	32.3%

Getiri vs. Endüstri: BACK geçen yıl % 7.5 oranında getiri sağlayan US Healthcare sektörünün gerisinde kaldı.

Getiri vs Piyasa: BACK geçen yıl % 32.3 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is BACK's price volatile compared to industry and market?
BACK volatility
BACK Average Weekly Movement	11.5%
Healthcare Industry Average Movement	7.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: BACK hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: BACK 'nin haftalık oynaklığı son bir yılda 24% dan 12% a düştü, ancak hâlâ US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2000	3	Faith Zaslavsky	www.imacholdings.com

IMAC Holdings, Inc. önemli faaliyetlere sahip değildir. Daha önce, yenilikçi tıbbi gelişmeler ve bakım rejenerasyon merkezleri ve backspace kliniklerinin sahibi ve yöneticisiydi. Şirket 2000 yılında kurulmuştur ve merkezi Brentwood, Tennessee'dedir.

IMAC Holdings, Inc. Temel Bilgiler Özeti

IMAC Holdings'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
BACK temel i̇stati̇sti̇kler
Piyasa değeri	US$1.79m
Kazançlar(TTM)	-US$5.63m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.3x

F/K Oranı

BACK aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
BACK gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$860.77k
Brüt Kâr	-US$860.77k
Diğer Giderler	US$4.77m
Kazançlar	-US$5.63m

Son Raporlanan Kazançlar

Mar 31, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-3.27
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

BACK uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

BACK Stoklara Genel Bakış

Risk Analizi

IMAC Holdings, Inc. Rakipler

NYSEAM:SSY

US$5.3m

NasdaqCM:TOI

US$13.0m

OTCPK:USNU

US$13.6m

NasdaqCM:IVP

US$5.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

IMAC Holdings Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10 Q

IMAC Holdings, Inc. announced delayed 10-Q filing

IMAC Holdings, Inc. announced that it expects to receive $3.74 million in funding from a group of investors

Imac Holdings Inc. Announces the Launch of an Entirely New Precision Oncology Assay for Breast Cancer Treatment Decision Making Utilizing the Reverse Phase Protein Array (Rppa) Technology Through Its Newly Established Subsidiary, Ignite Proteomics Llc

IMAC Holdings, Inc. Announces Resignation of Cary Sucoff as Director

IMAC Holdings, Inc. announced delayed 10-Q filing

Recent updates

IMAC Holdings Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10 Q

IMAC Holdings, Inc. announced delayed 10-Q filing

IMAC Holdings, Inc. announced that it expects to receive $3.74 million in funding from a group of investors

Imac Holdings Inc. Announces the Launch of an Entirely New Precision Oncology Assay for Breast Cancer Treatment Decision Making Utilizing the Reverse Phase Protein Array (Rppa) Technology Through Its Newly Established Subsidiary, Ignite Proteomics Llc

IMAC Holdings, Inc. Announces Resignation of Cary Sucoff as Director

IMAC Holdings, Inc. announced delayed 10-Q filing

IMAC Holdings, Inc. announced that it has received $1 million in funding

IMAC Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

IMAC Holdings, Inc. Announces Chief Executive Officer Changes

IMAC Holdings, Inc. Announces Board Resignations

Theralink Technologies, Inc. (OTCPK:THER) cancelled the acquisition of IMAC Holdings, Inc. (NasdaqCM:BACK) in a reverse merger transaction.

IMAC Holdings, Inc. announced delayed annual 10-K filing

Insufficient new directors

IMAC Holdings, Inc. Announces Executive Changes

IMAC Holdings Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement of $2.5 Million for Continued Listing on the Nasdaq Capital Market Under Listing Rule 5550(b)(1)

IMAC Holdings, Inc. announced delayed 10-Q filing

Insufficient new directors

IMAC Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

IMAC Holdings, Inc. Receive Non-Compliance Letter from Nasdaq

IMAC Holdings, Inc. Announces 1-for-30 Reverse Stock Split to Regain Compliance

Price target decreased by 17% to US$1.25

IMAC Holdings Provides Nasdaq Compliance Update Regarding Minimum Stockholders' Equity Requirement and Minimum Bid Price Requirement

IMAC Holdings, Inc. announced that it has received $4.3 million in funding from Theralink Technologies, Inc. and other investors

IMAC Holdings, Inc., Annual General Meeting, Jul 05, 2023

IMAC Holdings Receives A Non-Compliance Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Theralink Technologies, Inc. (OTCPK:THER) entered into a definitive agreement and plan of merger to acquire IMAC Holdings, Inc. (NasdaqCM:BACK) in a reverse merger transaction.

IMAC Holdings, Inc. announced delayed 10-Q filing

IMAC Holdings, Inc.'s (NASDAQ:BACK) Business And Shares Still Trailing The Industry

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$5.00

IMAC Holdings, Inc. Launches E-Commerce Website for Vitamin and Supplement Line

IMAC Holdings Receives Notice from The Nasdaq Stock Market Regarding Minimum Bid Price Requirement

IMAC Holdings, Inc. Announces Completion of Third Cohort of Its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson's Disease

Consensus estimates of losses per share improve by 10%

IMAC Holdings, Inc. Announces Addition of Medical Weight Loss Services to IMAC Regeneration Centers

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

IMAC Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $3.925 million.

IMAC Holdings, Inc. Adds Stretch Services At the Backspace

Price target decreased to US$5.50

IMAC Holdings, Inc. Announces the Launch of Spinal Health and Wellness Products and Supplements

IMAC Holdings, Inc., Annual General Meeting, Jul 06, 2022

IMAC Holdings, Inc. announced delayed annual 10-K filing

IMAC Holdings, Inc. Announces Completion of Second Cohort of Its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’S Disease

IMAC Holdings, Inc. Announces Executive Changes

Imac Holdings, Inc. Announces Relocates of Growing Clinic in St. Louis Area

Third quarter 2021 earnings released: US$0.068 loss per share (vs US$0.12 loss in 3Q 2020)

Is IMAC Holdings (NASDAQ:IMAC) Using Debt In A Risky Way?

Consensus EPS estimates fall to -US$0.38

Price target decreased to US$3.50

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.20 loss in 2Q 2020)

IMAC Holdings, Inc. Announces Initiation of Second Cohort of Its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease

IMAC Holdings Launches Acute Care Services for Musculoskeletal Injuries

IMAC Holdings, Inc. (NasdaqCM:IMAC) agreed to acquire Active Medical Center Ltd.

IMAC Holdings, Inc. (NasdaqCM:IMAC) acquired Fort Pierce Chiropractic.

IMAC expands Florida presence with Fort Pierce Chiropractic acquisition for undisclosed amount

Imac Holdings, Inc. Introduces the Back Space - First In-Store Chiropractic and Spinal Care Location Within Walmart

Consensus EPS estimates increase to -US$0.34

Consensus revenue estimates fall to US$14.3m

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.18 loss in 1Q 2020)